Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;42(7):1839-1846.
doi: 10.1007/s10067-023-06528-5. Epub 2023 Feb 13.

Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study

Yingying Chen #  1   2   3   4 , Rongli Li #  1   2   3   4 , Xuan Luo  1   2   3   4 , Tianmin Wu  5 , Jieqiong Li  1   2   3   4 , Zheng Liu  1   2   3   4 , Yu Peng  1   2   3   4 , Hui Lu  1   2   3   4 , Linyi Peng  1   2   3   4 , Jiaxin Zhou  1   2   3   4 , Yan Zhao  1   2   3   4 , Xiaofeng Zeng  1   2   3   4 , Yunyun Fei  6   7   8   9 , Wen Zhang  10   11   12   13
Affiliations

Comparison of the efficacy and safety of leflunomide versus mycophenolate mofetil in treating IgG4-related disease: a retrospective cohort study

Yingying Chen et al. Clin Rheumatol. 2023 Jul.

Abstract

Objective: Combination therapy of glucocorticoids (GCs) plus leflunomide (LEF) and GCs plus mycophenolate mofetil (MMF) was reported to have good efficacy and safety in the management of IgG4-RD. However, studies comparing the efficacy and safety of these two combination therapies were unavailable. Herein, this study aimed to compare the efficacy and safety of GCs plus LEF and GCs plus MMF in treating IgG4-RD.

Methods: This study included 130 newly diagnosed IgG4-RD patients who received the therapy of GCs plus LEF (group I) and GCs plus MMF (group II). Clinical data at baseline and after treatment, treatment response, relapse rate, and adverse effects were recorded and analyzed.

Results: Patients in both groups responded well to the treatment in the 1st-month follow-up, and 100% of patients achieved treatment response. However, at the 6th and 12th-month follow-up, the total response rate of group II was higher than that in group I (75.6 vs. 53.7%, p = 0.038 and 85.4% vs. 61.0%, p = 0.013, respectively). In addition, the duration of disease remission in group II was longer than that in group I (9 (6-9) vs. 6 (6-6) months, p = 0.014). Moreover, more patients in group I had adverse effects compared with group II (36.6 vs. 7.3%, p < 0.01); and the most common adverse events of LEF were rash (12.2%) and elevation of liver enzymes (9.8%).

Conclusion: The combination therapy of GCs plus low-dose MMF had better efficacy and safety in the management of IgG4-RD compared with the therapy of GCs plus LEF.

Keywords: Efficacy; IgG4-related disease; Leflunomide; Mycophenolate.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Kamisawa T, Zen Y, Pillai S, Stone JH (2015) IgG4-related disease. Lancet (London England) 385(9976):1460–1471 - DOI - PubMed
    1. Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K et al (2003) A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 38(10):982–984 - DOI - PubMed
    1. Van Moerkercke W, Verhamme M, Doubel P, Meeus G, Oyen R, Van Steenbergen W (2010) Autoimmune pancreatitis and extrapancreatic manifestations of IgG4-related sclerosing disease. Acta Gastro-Enterol Belg 73(2):239–246
    1. Chen Y, Zhao JZ, Feng RE, Shi JH, Li XM, Fei YY et al (2016) Types of organ involvement in patients with immunoglobulin G4-related disease. Chin Med J 129(13):1525–1532 - DOI - PubMed - PMC
    1. Cheuk W, Chan JK (2010) IgG4-related sclerosing disease: a critical appraisal of an evolving clinicopathologic entity. Adv Anat Pathol 17(5):303–332 - DOI - PubMed

MeSH terms

LinkOut - more resources